Medtronic touts FDA win, commercial launch of next-gen FlexCath sheath

Wed, 01/16/2013 - 2:49pm
Mass Device

Medical device company Medtronic wins FDA clearance for its 2nd-generation FlexCath Advance steerable sheath for use with the Arctic Front Advance cryoablation balloon system.

Medtronic's Arctic Front Advance cryoablation balloon system

Medical device maker Medtronic (NYSE:MDT) this week touted FDA clearance for its next-generation FlexCath Advance steerable sheath, launching U.S. commercial efforts immediately.

The new FlexCath Advance sheath is designed to work with Medtronic's Arctic Front Advance cryoablation balloon system, which treats irregular heartbeat by blocking electrical signals that trigger erratic rhythms in the heart's upper chambers.

The new sheath has several design improvements and is easier to use, according to a press release.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.